RVMD
Revolution Medicines, Inc.The numbers · FY2025, filed
SEC EDGARAll filed figures
Snapshot
SEC EDGAR · FY 2025-12-31Revenue by fiscal year
Operating leverage — margins
Financials, annual · income and cash flowSEC EDGAR · open ▸
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $29.4M | $35.4M | $11.6M | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-188.0M | $-258.3M | $-487.2M | $-689.5M | $-1.2B |
| Net Income | $-187.0M | $-249.0M | $-436.0M | $-600.0M | $-1.1B |
| Diluted EPS | $-2.57 | $-3.08 | $-3.86 | $-3.58 | $-5.95 |
| Operating Cash Flow | $-147.2M | $-224.4M | $-350.6M | $-557.4M | $-897.7M |
| Free Cash Flow | $-153.7M | $-235.2M | $-358.3M | $-567.7M | $-913.7M |
RVMD story timeline
Company updates and connected market context, with the dated price move attached.
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
Revolution Medicines said the FDA granted Breakthrough Therapy Designation to RASONQUE in combination with gemcitabine and nab-paclitaxel for treatment-naïve metastatic pancreatic cancer. The designation can accelerate regulatory interaction, but the commercial case still depends on clinical data and a path from designation to approval.
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
The FDA has approved Revolution Medicines' RASONQUE (daraxonrasib) as the first broad RAS-targeted medicine for metastatic pancreatic cancer. The approval opens a new drug class in one of oncology's hardest-to-treat cancers and gives Revolution Medicines its first commercial product.
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.